Heather Landau - Concepedia

Author

Heather Landau

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

Bennett, Elizabeth, Carol D. Karp, H J Landau, H Landau, H. J. Landau, H. Landau, H.J. Landau, Heather J Landau, Heather J. Landau, Heather Jolie Landau

514

Publications

7.8K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Medical College of Wisconsin Tufts Medical Center University of Pennsylvania

About

Heather Landau is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	35	1.7K
2	Health Sciences	14	14	734
3	Blood Transplantation	4	4	367
4	Biochemistry	1	1	12
5	Biostatistics	1	1	50

Heather Landau

111

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister, New England Journal of Medicine	2012	1.1K
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial Edward A. Stadtmauer, Marcelo C. Pasquini, Beth Blackwell, Journal of Clinical Oncology	2019	256
Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium Isabelle Lousada, Raymond L. Comenzo, Heather Landau, Advances in Therapy	2015	249
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation Susan E. Prockop, Ekaterina Doubrovina, Stephanie Suser, Journal of Clinical Investigation	2019	223
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction Morie A. Gertz, Heather Landau, Raymond L. Comenzo, Journal of Clinical Oncology	2016	204
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study Anita D’Souza, Angela Dispenzieri, Baldeep Wirk, Journal of Clinical Oncology	2015	200
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial Sarah A. Holstein, Sin‐Ho Jung, Paul G. Richardson, The Lancet Haematology Hematological MalignancyOncologyMarrow TransplantationTransplantationStem Cell Transplantation	2017	168
Predictors of survival in patients with systemic light‐chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone Dan I. Lebovic, James E. Hoffman, B. M. Levine, British Journal of Haematology Systemic Light-chainHeart FailureTransplantationCardiovascular DiseaseMonthly Oral Melphalan	2008	117
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma Ola Landgren, Malin Hultcrantz, Benjamin Diamond, JAMA Oncology	2021	114
Salvage Second Hematopoietic Cell Transplantation in Myeloma Laura C. Michaelis, Ayman Saad, Xiaobo Zhong, Biology of Blood and Marrow Transplantation	2013	109

Page 1